北京分校

考试资讯

      考研英语水平的进步，不仅要记单词，还需要阅读外语文献等资料。接下来，小编为2024考研者们，整理出——2024考研英语同源外刊3月:新药物可能终结全球肥胖流行，供考生参考。

2024考研英语同源外刊3月:新药物可能终结全球肥胖流行

New drugs could spell an end to the world’s obesity epidemic

新药物可能会终结全球肥胖流行

A new type of drug is generating excitement among the rich and the beautiful. Just a jab a week, and the weight falls off. Elon Musk swears by it; influencers sing its praises on TikTok; suddenly slimmer Hollywood starlets deny they have taken it. But the latest weight-loss drugs are no mere cosmetic enhancements. Their biggest beneficiaries will be not celebrities in Los Angeles or Miami but billions of ordinary people around the world whose weight has made them unhealthy.

一种新型的药物在富人和美女中引起了欢呼。每周只需注射一针，体重就会下降。埃隆·马斯克对其推崇备至;网红们在TikTok上为它唱赞歌;突然变瘦的好莱坞女明星否认服用过它。但是，新的减肥药带来的可不只是外貌上的变化。较大的受益者将不是洛杉矶或迈阿密的名人，而是全世界数十亿被体重拖累健康的普通人。

Treatments for weight loss have long ranged from the well-meaning and ineffective to the downright dodgy. The new class of drugs, called GLP-1 receptor agonists, seems actually to work. Semaglutide, developed by Novo Nordisk, a Danish pharmaceutical firm, has been shown in clinical trials to lead to weight loss of about 15%. It is already being sold under the brand name Wegovy in America, Denmark and Norway and will soon be available in other countries; Ozempic, a lower-dose version, is a diabetes drug that is also being used “off label” for weight loss.

长期以来，减肥的治疗方法从善意的、无效的到完全不可靠的都有。新的一类药物，称为GLP-1受体激动剂，似乎确实有效。由丹麦制药公司诺和诺德(Novo Nordisk)开发的索马鲁肽(Semaglutide)，已经在临床试验中被证明可以使体重减轻约15%。它已经以Wegovy的品牌名称在美国、丹麦和挪威销售，并将很快在其他国家上市;Ozempic是一种低剂量的糖尿病药物，也被“非标”用于减肥。

A rival GLP-1 drug, made by Eli Lilly, an American firm, is due to come on sale later this year and is more effective still. Analysts think the market for GLP-1 drugs could reach $150bn by 2031. not far off the market for cancer drugs today. Some think they could become as common as beta blockers or statins. The drugs could not have arrived at a better time. In 2020 two-fifths of the world’s population were overweight or obese.

由美国礼来公司生产的一种竞争性GLP-1药物将于今年晚些时候上市，而且更加有效。分析师认为，到2031年，GLP-1药物的市场可能达到1500亿美元，与今天的癌症药物市场相差不远。一些人认为它们可能会变得像β受体阻滞剂或他汀类药物一样普遍。这些药来得正是时候。2020年，全球五分之二的人口超重或肥胖。

 

单词

spell /spel/ vt. 意味着;

obesity /oʊˈbiːsəti/ n. 过度肥胖，肥胖症;

epidemic /ˌepɪˈdemɪk/ n. 流行病，传染病;蔓延;

generate /ˈdʒenəreɪt/ vt. 产生;带来;生成;创造;引起;

jab /dʒæb/ n. 打针;

fall off 减少;下降;

swear /swer/ vi. 郑重承诺，发誓;保证(所说属实);

influencer /ˈɪnfluənsə(r)/ n. 有影响力者;有影响力的人;

slim /slɪm/ adj. 苗条的，纤细的;单薄的;些许的;

starlet /ˈstɑːrlət/ n. 尚未成名的年轻女演员;

enhancement /ɪnˈhænsmənt/ n. 改善;增加;改进手段;

beneficiary/ˌbenɪˈfɪʃieri/ n. 受惠者;受益人;

well-meaning /ˌwel ˈmiːnɪŋ/ adj. 善意的;出于好心的;

downright /ˈdaʊnraɪt/ adj. 完全的;彻头彻尾的，十足的;断然的;

dodgy /ˈdɑːdʒi/ adj. 可疑的;存在风险的;不佳的;

receptor /rɪˈseptər/ n. 感受器;受体;

agonist /ˈæɡənɪst/ n. 兴奋剂，激动剂;

      综上是“2024考研英语同源外刊3月:新药物可能终结全球肥胖流行”，希望对备战2024考研考生们有所帮助!让我们乘风破浪，终抵彼岸，考研加油!

推荐阅读：

2024考研英语同源外刊3月文章汇总

2024考研英语同源外刊2月文章汇总